PTC Therapeutics, Huntington's Disease and Fast Track
PTC Therapeutics Says FDA Grants Fast Track Designation For PTC518 To Treat Huntington's Disease
PTC Therapeutics, Inc. (PTCT) announced Thursday that the FDA has granted Fast Track designation to the PTC518 program for the
PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track Designation
PTC Therapeutics' treatment for Huntington's disease has received a fast track designation from U.S. health regulators. The biopharmaceutical company said Thursday that the Food and Drug Administration granted the designation to the PTC518 program which aims to reduce the production of mutated Huntington protein.
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's disease. Fast Track designation is awarded to promising therapies for diseases of high unmet need.
Positive Outlook on PTC Therapeutics: Buy Rating Backed by Fast Track Designation and Promising Clinical Trials
Robert W. Baird analyst Joel Beatty has maintained their bullish stance on PTCT stock, giving a Buy rating on September 16. Joel Beatty has
PTC Therapeutics, Inc.: FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's
PTC Therapeutics: Positive HD Data Along With NDA Submission Brings Further Value
PTC Therapeutics, Inc. got a dose-dependent lowering of mutant Huntingtin protein in both the blood and CSF of HD patients ...
Benzinga on MSN3mon
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
In the CSF, dose-dependent mHTT lowering was also demonstrated, with lowering of 21% and 43% for 5mg and 10mg dose levels, ...
pharmaphorum7d
uniQure craters on Huntington’s gene therapy data
Meanwhile, there was another data drop in Huntington’s disease, as PTC Therapeutics reported interim data from its phase 2 PIVOT-HD study of small-molecule drug PTC518 at around the same time.
Hosted on MSN3mon
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
Last week, management reported encouraging interim data from the mid-stage PIVOT-HD study evaluating PTC518, its investigational treatment for Huntington's disease (HD). Following 12 months of ...
The Jerusalem Post Blogs19h
Israel News
The event, reportedly attended by over 10,500 people, highlighted the talents of the musicians while emphasizing the importance of inclusion. Information ...
Benzinga.com4y
PTC Therapeutics (NASDAQ:PTCT) Stock Quotes, Forecast and News Summary
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on ...
The New York Times2d
World News
No damage was reported from the missile, but it was a sign of defiance from the Lebanese militia after a week of withering Israeli attacks. Half a million people are displaced in Lebanon, the ...